Nio Y, Inamoto T, Ohgaki K, Kan N, Hori T, Nakayama N, Yamasaki N, Hikasa Y
Nihon Geka Gakkai Zasshi. 1985 Jan;86(1):8-22.
In this paper, we demonstrated a selection system of anti-cancer agents (ACA) using discontinuous Ficoll density gradient method (DFDGM) for purification of tumor cells and 3H-Thymidine for evaluation of DNA synthesis of tumor cells. The tumor cells, purified to more than 80% by DFDGM, were contacted with ACAs for 3 days from the culture initiation and tumor suppression rate (TSR) by ACAs were calculated by following formula; TSR = ACA(-)cpm-ACA(+)cpm-background cpm divided by ACA(-)cpm-background cpm X 100% 7 ACAs; Mitomycin C (MMC), Adriamycin (ADM), 5-Fluorouracil (5-FU), Cytosine Arabinoside (Ara-C), Carbazilquinone (CQ), ACNU and Cis-platinum (CDDP) were examined in 106 cancers; 60 breast cancers, 18 gastric cancers, 23 colorectal cancers and 5 others. ADM and CQ showed high TSR against breast cancers, CQ against gastric cancers, and 5-FU and CQ against colorectal cancers, respectively. The reliability of this ACA selection system should be evaluated by future clinical studies, however, we stress that ACA should be selected by not only the effect on tumor cells but also the effect on immunity of the host, in future.
在本文中，我们展示了一种抗癌药物（ACA）筛选系统，该系统使用不连续菲可密度梯度法（DFDGM）纯化肿瘤细胞，并使用³H-胸腺嘧啶核苷评估肿瘤细胞的DNA合成。通过DFDGM纯化至80%以上的肿瘤细胞，从培养开始起与ACA接触3天，并通过以下公式计算ACA的肿瘤抑制率（TSR）；TSR =（ACA阴性cpm - ACA阳性cpm - 背景cpm）/（ACA阴性cpm - 背景cpm）×100%。对7种ACA进行了检测；丝裂霉素C（MMC）、阿霉素（ADM）、5-氟尿嘧啶（5-FU）、阿糖胞苷（Ara-C）、卡巴醌（CQ）、嘧啶亚硝脲（ACNU）和顺铂（CDDP），检测了106例癌症；60例乳腺癌、18例胃癌、23例结直肠癌和5例其他癌症。ADM和CQ对乳腺癌显示出高TSR，CQ对胃癌显示出高TSR，5-FU和CQ对结直肠癌分别显示出高TSR。然而，该ACA筛选系统的可靠性应由未来的临床研究评估，我们强调，未来选择ACA时不仅应考虑其对肿瘤细胞的作用，还应考虑其对宿主免疫力的作用。
